The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial to establish the safety and preliminary efficacy of the combination of docetaxel, prednisone, and SOM 230 in metastatic castrate-resistant prostate cancer (CRPC).
H. M. Vankayala
No relevant relationships to disclose
L. K. Heilbrun
No relevant relationships to disclose
J. A. Fontana
No relevant relationships to disclose
U. N. Vaishampayan
Honoraria - Novartis
Research Funding - Novartis